Chemomab Therapeutics Ltd DRC (CMMB) Key Ratios
$2.86
As on 04-Sep-2026 13:34EDT
Market cap
$20 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | 55.19 | 22.40 | 4.64 |
| Net Profit | -24.21 | -7.06 | 35.72 | 21.01 | 0.12 |
| EPS | -23.83 | 22.49 | 46.01 | 24.15 | 13.50 |
| Book Value | -- | -- | 119.67 | -49.79 | -41.64 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -83.97 | -68.61 | -72.33 | -69.54 | -91.34 |
| Return on Capital
| -82.64 | -67.66 | -- | -68.68 | -89.25 |
| Return on Assets
| -68.01 | -57.60 | -46.42 | -58.46 | -71.30 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | 0.02 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
-68.68
|
-89.25
|
-90.00
|
-56.28
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-72.33
Lower than Peers by 31.94
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
-72.33
|
-69.54
|
-91.34
|
-91.02
|
-56.60
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-46.42
Lower than Peers by 15.44
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
-46.42
|
-58.46
|
-71.30
|
-74.28
|
-51.47
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Growth
55.19
Higher than Peers by 55.99
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
55.19
|
35.09
|
42.11
|
10.77
|
-130.72
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
35.72
Higher than Peers by 43.02
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
35.72
|
35.50
|
42.43
|
12.39
|
-121.56
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
46.01
Higher than Peers by 31.36
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
46.01
|
-0.56
|
0.90
|
0.22
|
-1.17
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-35.17
Lower than Peers by 25.00
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
-35.17
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
--
|
0.02
|
0.02
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
--
|
0.01
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
6.41
Higher than Peers by 0.60
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
6.41
|
9.08
|
4.98
|
4.32
|
6.18
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
6.41
Higher than Peers by 0.72
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
6.41
|
--
|
4.98
|
4.53
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
--
|
--
|
--
|
-80.83
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
0.01
|
-3,556.42
|
-5,667.86
|
-8,522.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
2,893.82
|
3,940.51
|
6,023.10
|
9,559.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
-1.43
|
-2.45
|
-0.07
|
-0.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.30
Lower than Peers by 2.89
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
2.30
|
1.05
|
2.52
|
0.10
|
0.26
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.33
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
0.33
|
-0.27
|
-1.37
|
0.70
|
1.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
20
Lower than Peers by 126
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Chemomab Therapeutics Ltd DRC (CMMB)
|
20
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|